Ascendis Pharma to Replace ADSs with Direct Nasdaq Listing

Event summary

  • Ascendis Pharma will list ordinary shares directly on Nasdaq on April 20, 2026, replacing its American Depositary Shares (ADSs).
  • ADS holders will receive one ordinary share for each ADS held.
  • The move aims to broaden global investment access and potentially enhance institutional ownership.
  • Ordinary shares will trade under the same ticker symbol 'ASND' but with a new CUSIP number (K08588103) and ISIN (DK0060606333).

The big picture

Ascendis Pharma's transition from ADSs to a direct listing of ordinary shares aligns with a broader trend among international companies seeking to streamline access for global investors. This move could enhance liquidity and attract institutional investors, particularly if it leads to inclusion in major equity indexes. The shift also reflects Ascendis' strategic focus on expanding its investor base as it positions itself as a leading global biopharma company.

What we're watching

Market Dynamics
How the shift to ordinary shares will affect trading liquidity and institutional ownership.
Index Inclusion
Whether the direct listing will facilitate inclusion in key equity indexes.
Execution Risk
The pace at which ADS holders exchange shares and the potential impact on trading dynamics.